bit.bio raises $25M Series D as demand for its human cell models grows
bit.bio, a Cambridge-based biotechnology company, has secured $25M in Series D funding ten months after its previous investment round. The funding includes backing from existing investor M&G Investments and Jonathan Milner, founder and former CEO of research tools company Abcam. The company develops human cell models and sees growing market demand for its products.
Key points
- bit.bio raised $25M in Series D funding
- Backed by M&G Investments and Abcam founder Jonathan Milner
- Company focuses on human cell models with growing customer demand
Summary and key points written by AI from the headline and a short excerpt, so they can be incomplete or wrong. The Next Web did the reporting; read the original for the full story.
Read the full story at The Next Web
